Imsidolimab

Name: Imsidolimab in Generalized pustular psoriasis: Administration
Published: 2026-09-14T15:39:06-04:00

Generalized pustular psoriasis

Manufacturer: Vanda Pharmaceuticals
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Dosing and administration

Administration

1 evidence topic · 1 source

Administration setting in the clinical protocol

“ANB019 should be administered in an environment under close supervision of a physician and where full resuscitation facilities are immediately available.” (opens the source at this quote in a new tab)